ArticleJournal of nutritional science2021
Comparison of edible brown algae extracts for the inhibition of intestinal carbohydrate digestive enzymes involved in glucose release from the diet.
Article in Journal of nutritional science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 27 citations in OpenAlex.
- Effects of an Extract of the Brown SeaweedMarine drugs · 2023Trial
- Comparative Characterisation and In Vitro Metabolic Bioactivities of Fucoidan-Rich Extracts from Three South African Brown Macroalgae.Molecules (Basel, Switzerland) · 2026Article
- Research Progress on Polyphenols and Polysaccharides from Marine Seaweeds: Promising Diabetes Management Natural Products.Marine drugs · 2026Review
- Phlorotannins and glycolipid metabolism: comprehensive regulatory roles mediated by the gut microbiota.Frontiers in nutrition · 2026Review
- Effects of Chlorella vulgaris, Microchloropsis Gaditana and Gracilaria vermiculophylla algae extracts on maturing and mature 3T3-L1 adipocytes.Scientific reports · 2025Article
- Chemical Profiling and Biological Activities ofScientifica · 2025Article
- Article
- Evaluating the Potential ofPharmaceuticals (Basel, Switzerland) · 2023Review
- Cochayuyo (Foods (Basel, Switzerland) · 2023Article
- Algae-Derived Natural Products in Diabetes and Its Complications-Current Advances and Future Prospects.Life (Basel, Switzerland) · 2023Review
- Anti-Steatotic Effects ofNutrients · 2023Article
- Characterization ofMarine drugs · 2022Article
- Citrus Flavanone Narirutin, In Vitro and In Silico Mechanistic Antidiabetic Potential.Pharmaceutics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type II diabetes is considered the most common metabolic disorder in the developed world and currently affects about one in ten globally. A therapeutic target for the management of type II diabetes is the inhibition of α- glucosidase, an essential enzyme located at the brush border of the small intestinal epithelium. The inhibition of α-glucosidase results in reduced digestion of carbohydrates and a decrease in postprandial blood glucose. Although pharmaceutical synthetic inhibitors are available, these are usually associated with significant gastrointestinal side effects. In the present study, the impact of inhibitors derived from edible brown algae is being investigated and compared for their effect on glycaemic control. Carbohydrate- and polyphenolic-enriched extracts derived from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.